<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-11-30" updated="2019-12-02">
  <drugbank-id primary="true">DB09449</drugbank-id>
  <drugbank-id>DB09127</drugbank-id>
  <drugbank-id>DB11083</drugbank-id>
  <drugbank-id>DB09524</drugbank-id>
  <drugbank-id>DB09542</drugbank-id>
  <drugbank-id>DB09468</drugbank-id>
  <drugbank-id>DB11084</drugbank-id>
  <drugbank-id>DB09482</drugbank-id>
  <drugbank-id>DB09469</drugbank-id>
  <drugbank-id>DB09525</drugbank-id>
  <drugbank-id>DBSALT001969</drugbank-id>
  <name>Sodium phosphate, monobasic</name>
  <description>Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.</description>
  <cas-number>7558-80-7</cas-number>
  <unii>KH7I04HPUU</unii>
  <average-mass>119.977</average-mass>
  <monoisotopic-mass>119.958839739</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19446</ref-id>
        <pubmed-id>17652123</pubmed-id>
        <citation>Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24.</citation>
      </article>
      <article>
        <ref-id>A19447</ref-id>
        <pubmed-id>18645612</pubmed-id>
        <citation>Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521.</citation>
      </article>
      <article>
        <ref-id>A19448</ref-id>
        <pubmed-id>19298584</pubmed-id>
        <citation>Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27.</citation>
      </article>
      <article>
        <ref-id>A19449</ref-id>
        <pubmed-id>20958267</pubmed-id>
        <citation>Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377.</citation>
      </article>
      <article>
        <ref-id>A19450</ref-id>
        <pubmed-id>23398154</pubmed-id>
        <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L798</ref-id>
        <title>FDA Guide: Sodium Phosphate Tablet</title>
        <url>https://www.fda.gov/downloads/drugs/drugsafety/ucm134684.pdf</url>
      </link>
      <link>
        <ref-id>L799</ref-id>
        <title>ChemIDPlus: Sodium Phosphate</title>
        <url>https://chem.nlm.nih.gov/chemidplus/rn/7558-80-7</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used to treat constipation or to clean the bowel before a colonoscopy [FDA Label].</indication>
  <pharmacodynamics>Sodium phosphate inceases fecal water content to increase mobility through the large intestine [A19446].</pharmacodynamics>
  <mechanism-of-action>Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen [A19446].</mechanism-of-action>
  <toxicity>Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats [L799]. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma [A19449]. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients [A19448].</toxicity>
  <metabolism/>
  <absorption>Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h [A19448].</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.</description>
    <direct-parent>Alkali metal phosphates</direct-parent>
    <kingdom>Inorganic compounds</kingdom>
    <superclass>Mixed metal/non-metal compounds</superclass>
    <class>Alkali metal oxoanionic compounds</class>
    <subclass>Alkali metal phosphates</subclass>
    <alternative-parent>Inorganic oxides</alternative-parent>
    <alternative-parent>Inorganic sodium salts</alternative-parent>
    <substituent>Alkali metal phosphate</substituent>
    <substituent>Inorganic oxide</substituent>
    <substituent>Inorganic salt</substituent>
    <substituent>Inorganic sodium salt</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001970</drugbank-id>
      <name>Sodium phosphate, monobasic, dihydrate</name>
      <unii>5QWK665956</unii>
      <cas-number>13472-35-0</cas-number>
      <inchikey>VBJGJHBYWREJQD-UHFFFAOYSA-M</inchikey>
      <average-mass>156.006</average-mass>
      <monoisotopic-mass>155.97996919</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001971</drugbank-id>
      <name>Sodium phosphate, monobasic, monohydrate</name>
      <unii>593YOG76RN</unii>
      <cas-number>10049-21-5</cas-number>
      <inchikey>BBMHARZCALWXSL-UHFFFAOYSA-M</inchikey>
      <average-mass>137.991</average-mass>
      <monoisotopic-mass>137.96940451</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Disodium hydrogen phosphate anhydrous</synonym>
    <synonym language="english" coder="">Monosodium dihydrogen monophosphate</synonym>
    <synonym language="english" coder="">Monosodium dihydrogen orthophosphate</synonym>
    <synonym language="english" coder="">Monosodium monophosphate</synonym>
    <synonym language="english" coder="">Monosodium phosphate, anhydrous</synonym>
    <synonym language="english" coder="">Phosphoric acid, monosodium salt, anhydrous</synonym>
    <synonym language="english" coder="">Sodium acid phosphate</synonym>
    <synonym language="english" coder="">Sodium biphosphate, anhydrous</synonym>
    <synonym language="english" coder="">Sodium dihydrogen phosphate, anhydrous</synonym>
    <synonym language="english" coder="">Sodium orthophosphate</synonym>
    <synonym language="english" coder="">Sodium orthophosphate monobasic</synonym>
    <synonym language="english" coder="">Sodium phosphate monobasic</synonym>
    <synonym language="english" coder="">Sodium phosphate monobasic (anhydrate)</synonym>
    <synonym language="english" coder="">Sodium phosphate monobasic (anhydrous)</synonym>
    <synonym language="english" coder="">Sodium phosphate, monobasic</synonym>
    <synonym language="english" coder="">Sodium phosphate, monobasic anhydrous</synonym>
    <synonym language="english" coder="">Sodium phosphate,monobasic</synonym>
    <synonym language="english" coder="">Sodium primary phosphate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Additive Formula 3</name>
      <labeller>Terumo Bct, Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN001214</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Additive Formula 3</name>
      <labeller>Terumo Bct, Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN001214</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Additive Formula 3</name>
      <labeller>Terumo Bct, Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-828</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN001214</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Additive Solution Formula 3 As-3</name>
      <labeller>Terumo Bct, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02324393</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6492</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6464</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6445</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6484</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6449</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6499</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6444</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6486</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6483</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6453</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6459</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6488</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6487</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6493</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6475</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6496</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6494</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6482</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6485</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6470</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Cit Phos Dex Adenine Sol USP</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01960865</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN170401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN170401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Solution Citrate Phosphate Dextrose (cpd)</name>
      <labeller>Maco Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02444100</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>As 3</name>
      <labeller>Terumo BCT Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-966</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN001214</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Av-Phos 250 Neutral</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-152</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Azuphen Mb</name>
      <labeller>Burel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35573-314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-28</started-marketing-on>
      <ended-marketing-on>2016-11-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Blood Pack Unit Cpd</name>
      <labeller>Fenwal Labs, Division of Baxter Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00273953</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-14</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cpd</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN170401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpd Adenine Cpda 1</name>
      <labeller>Fenwal Labs, Division of Baxter Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00516775</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-11</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cpd Solution</name>
      <labeller>Laboratorios Grifols s.a.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02421135</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cpd/adsol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpd/adsol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpd/adsol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6478</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN900223</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6481</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN900223</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6479</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN900223</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6344</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9398</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6319</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6331</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6336</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9395</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6327</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9394</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9393</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6332</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPDA-1 Blood Collection System</name>
      <labeller>Haemonetics Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53157-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN800077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPDA-1 Blood Collection System</name>
      <labeller>Haemonetics Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53157-730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN800077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Darpaz</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-281</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-01</started-marketing-on>
      <ended-marketing-on>2011-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-764</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-13</started-marketing-on>
      <ended-marketing-on>2020-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-11</started-marketing-on>
      <ended-marketing-on>2018-06-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-2195</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7676</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-28</started-marketing-on>
      <ended-marketing-on>2018-05-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Kaiser Foundations Hospitals</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>E-Z Cups</name>
      <labeller>Dental Resources of Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00472824</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-13</ended-marketing-on>
      <dosage-form>Paste</dosage-form>
      <strength/>
      <route>Dental</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Elliotts B</name>
      <labeller>Lukare Medical, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55792-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength/>
      <route>Intrathecal</route>
      <fda-application-number>NDA020577</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Elliotts B</name>
      <labeller>QOL Medical, LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>67871-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength/>
      <route>Intrathecal</route>
      <fda-application-number>NDA020577</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eyesaline Eyewash</name>
      <labeller>Fendall, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01988220</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-16</started-marketing-on>
      <ended-marketing-on>2005-08-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gent-L-tip Phosphate Enema</name>
      <labeller>Chester Packaging</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00528463</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on>2001-09-26</ended-marketing-on>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Glycerolyte 57 Solution</name>
      <labeller>Fresenius Kabi Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00783668</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Haemonetics Additive Solution Formula 3 (AS-3)</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>57826-462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BN000127</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Haemonetics Additive Solution Formula 3 (AS-3)</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>57826-460</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BN000127</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Haemonetics Anticoagulant Citrate Phosphate Double Dextrose Solution (CP2D)</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>57826-455</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BN000127</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hyolev Mb</name>
      <labeller>Burel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35573-301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-26</started-marketing-on>
      <ended-marketing-on>2016-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Indiomin Mb</name>
      <labeller>Burel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35573-315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-28</started-marketing-on>
      <ended-marketing-on>2016-10-24</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Instillation Medium for Immucyst</name>
      <labeller>Aventis Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01974505</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>2001-07-19</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravesical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>InterSol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9602</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN080041</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>InterSol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN080041</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ionosol and Dextrose</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-7373</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-05-08</started-marketing-on>
      <ended-marketing-on>2008-09-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA019514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ionosol B and Dextrose</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-7371</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-07-07</started-marketing-on>
      <ended-marketing-on>2011-10-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA019515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ionosol MB and Dextrose</name>
      <labeller>Icu Medical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0990-7372</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA019513</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ionosol MB and Dextrose</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-7372</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA019513</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>K Phos Neutral</name>
      <labeller>Beach Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0486-1125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>K-Phos No. 2</name>
      <labeller>Beach Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0486-1134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leucoflex CGP</name>
      <labeller>Maco Productions</labeller>
      <ndc-id/>
      <ndc-product-code>14498-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN040083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leukotrap WB System</name>
      <labeller>Haemonetics Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53157-736</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN800077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leukotrap WB System</name>
      <labeller>Haemonetics Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53157-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN800077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Me NaPhos MB Hyo 1</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-454</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Monobasic Sodium Phosphate and Dibasic Sodium Phosphate</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079247</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MTL1 Leucoflex</name>
      <labeller>Maco Productions</labeller>
      <ndc-id/>
      <ndc-product-code>14498-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN040083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nutricel Additive System - CP2D</name>
      <labeller>Medsep Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>62646-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA820915</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>OsmoPrep</name>
      <labeller>Salix Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>65649-701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021892</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>OsmoPrep</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5889</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021892</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phosenamine</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2011-03-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phosphasal</name>
      <labeller>Star Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0076-0902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phosphasal</name>
      <labeller>BioComp Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>44523-742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phospho-soda Buffered Saline Laxative</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00771678</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-12-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Phospho-Trin 250 Neutral</name>
      <labeller>Patrin Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>39328-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PMS-phosphates Solution</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01986147</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-07</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rejuvesol</name>
      <labeller>Citra Labs</labeller>
      <ndc-id/>
      <ndc-product-code>23731-7000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BN950522</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Riga Purgative Lemon Flav Liq</name>
      <labeller>Glendale Agencies</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00421367</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>1996-11-29</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-3405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2013-06-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-3450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2013-10-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>H and P Industries, Inc. dba Triad Group</labeller>
      <ndc-id/>
      <ndc-product-code>50730-2111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-05-22</started-marketing-on>
      <ended-marketing-on>2010-05-31</ended-marketing-on>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>part334</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2018-06-25</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-7391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA018892</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-3415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2016-04-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates Injection USP</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00896187</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Solucion InterSol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9603</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN080041</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solution Saline Sterile Aux Phosphates</name>
      <labeller>Omega Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00616958</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ssp+</name>
      <labeller>Maco Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02492075</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ssp+</name>
      <labeller>Maco Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02492067</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sterile Cord Blood Collection Unit</name>
      <labeller>Medsep Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>62646-791</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA800222</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sterile Cord Blood Collection Unit (MSC127D)</name>
      <labeller>Maco Productions</labeller>
      <ndc-id/>
      <ndc-product-code>14498-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN125552</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sterile Cord Blood Collection Unit (MSC128D)</name>
      <labeller>Maco Productions</labeller>
      <ndc-id/>
      <ndc-product-code>14498-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN125552</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)</name>
      <labeller>Terumo Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53877-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN820528</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>UR N-C Urinary Antiseptic</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-21</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uramit Mb</name>
      <labeller>Burel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35573-300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-26</started-marketing-on>
      <ended-marketing-on>2016-11-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Urelle</name>
      <labeller>MEDA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0037-6321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Urelle</name>
      <labeller>Jazz Pharmaceuticals Commercial Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>66663-219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uribel</name>
      <labeller>Mission Pharmacal Company</labeller>
      <ndc-id/>
      <ndc-product-code>0178-0740</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uribel</name>
      <labeller>Star Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0076-0111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Urimar-T</name>
      <labeller>Marnel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0682-0334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Urin D/S</name>
      <labeller>Llorens Pharmaceuticals International Division</labeller>
      <ndc-id/>
      <ndc-product-code>54859-701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uro-458</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uro-L</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on>2016-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uro-MP</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-456</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>UroAv-81</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-851</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>UroAv-81</name>
      <labeller>Apace Packaging, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>15338-502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>UroAv-B</name>
      <labeller>Apace Packaging, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>15338-503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>UroAv-B</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-852</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ustell</name>
      <labeller>Biocomp Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44523-743</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ustell</name>
      <labeller>Star Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0076-0903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Utac</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-199</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-01</started-marketing-on>
      <ended-marketing-on>2011-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Utira-C</name>
      <labeller>Hawthorn Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63717-513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-01</started-marketing-on>
      <ended-marketing-on>2010-01-28</ended-marketing-on>
      <dosage-form>Tablet, sugar coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vilamit MB</name>
      <labeller>Vilvet Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71186-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vilevev MB</name>
      <labeller>Vilvet Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71186-000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Virt Phos 250 Neutral</name>
      <labeller>Virtus Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76439-268</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-13</started-marketing-on>
      <ended-marketing-on>2017-04-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Virt-Phos 250 Neutral</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69543-268</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visicol</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5396</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021097</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visicol</name>
      <labeller>Salix Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65649-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-10-01</started-marketing-on>
      <ended-marketing-on>2012-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021097</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>OsmoPrep</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Darpaz</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Phosenamine</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Utac</name>
      <ingredients>Methenamine + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Monobasic Sodium Phosphate and Dibasic Sodium Phosphate</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Elliotts B</name>
      <ingredients>Calcium chloride + D-glucose + Magnesium sulfate + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Visicol</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Urelle</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ionosol and Dextrose</name>
      <ingredients>D-glucose + Potassium chloride + Potassium lactate + Sodium chloride + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Urin D/S</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Visicol</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Utira-C</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>UR N-C Urinary Antiseptic</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Uro-458</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Uro-L</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ustell</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Uribel</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Phosphasal</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Hyolev Mb</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Uramit Mb</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Azuphen Mb</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ionosol B and Dextrose</name>
      <ingredients>D-glucose + Dipotassium phosphate + Lactic acid + Magnesium chloride + Potassium chloride + Sodium chloride + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sterile Cord Blood Collection Unit (MSC128D)</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Uro-MP</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Urimar-T</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Indiomin Mb</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Rejuvesol</name>
      <ingredients>Adenine + Inosine + Pyruvic acid + Sodium phosphate, dibasic, unspecified form + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sterile Cord Blood Collection Unit (MSC127D)</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>UroAv-B</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>UroAv-81</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>UroAv-B</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>UroAv-81</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sterile Cord Blood Collection Unit</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>InterSol</name>
      <ingredients>Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic, unspecified form + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Elliotts B</name>
      <ingredients>Calcium chloride + D-glucose + Magnesium sulfate + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Urelle</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>As 3</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Me NaPhos MB Hyo 1</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd/adsol</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ustell</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Vilamit MB</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Vilevev MB</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Solucion InterSol</name>
      <ingredients>Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic, unspecified form + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Uribel</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd/adsol</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Additive Formula 3</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Additive Formula 3</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Additive Formula 3</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Nutricel Additive System - CP2D</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Av-Phos 250 Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Virt-Phos 250 Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Virt Phos 250 Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Phospho-Trin 250 Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>InterSol</name>
      <ingredients>Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic, unspecified form + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Leukotrap WB System</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPDA-1 Blood Collection System</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPDA-1 Blood Collection System</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ionosol MB and Dextrose</name>
      <ingredients>D-glucose + Lactic acid + Magnesium chloride + Monopotassium phosphate + Potassium chloride + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>OsmoPrep</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>K Phos Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>K-Phos No. 2</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Phosphasal</name>
      <ingredients>Hyoscyamine + Methenamine + Methylene blue + Phenyl salicylate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Haemonetics Additive Solution Formula 3 (AS-3)</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Haemonetics Additive Solution Formula 3 (AS-3)</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Haemonetics Anticoagulant Citrate Phosphate Double Dextrose Solution (CP2D)</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ionosol MB and Dextrose</name>
      <ingredients>D-glucose + Lactic acid + Magnesium chloride + Monopotassium phosphate + Potassium chloride + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd/adsol</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>MTL1 Leucoflex</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Leucoflex CGP</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Leukotrap WB System</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates Injection USP</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Additive Solution Formula 3 As-3</name>
      <ingredients>Adenine + Citric acid + Dextrose, unspecified form + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>PMS-phosphates Solution</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Phospho-soda Buffered Saline Laxative</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Blood Pack Unit Cpd</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Instillation Medium for Immucyst</name>
      <ingredients>Dipotassium phosphate + Sodium chloride + Sodium phosphate, monobasic + Water</ingredients>
    </mixture>
    <mixture>
      <name>Eyesaline Eyewash</name>
      <ingredients>Sodium chloride + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>E-Z Cups</name>
      <ingredients>Sodium fluoride + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Riga Purgative Lemon Flav Liq</name>
      <ingredients>Citric acid + Sodium bicarbonate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd Adenine Cpda 1</name>
      <ingredients>Adenine + Citric acid + Dextrose, unspecified form + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Gent-L-tip Phosphate Enema</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd Solution</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Solution Citrate Phosphate Dextrose (cpd)</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Cit Phos Dex Adenine Sol USP</name>
      <ingredients>Adenine + Citric acid + Dextrose, unspecified form + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Solution Saline Sterile Aux Phosphates</name>
      <ingredients>Sodium chloride + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Glycerolyte 57 Solution</name>
      <ingredients>Glycerin + Lactic acid + Potassium chloride + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ssp+</name>
      <ingredients>Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ssp+</name>
      <ingredients>Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids</category>
      <mesh-id>D000143</mesh-id>
    </category>
    <category>
      <category>Acids, Noncarboxylic</category>
      <mesh-id>D000148</mesh-id>
    </category>
    <category>
      <category>Agents that reduce seizure threshold</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anions</category>
      <mesh-id>D000838</mesh-id>
    </category>
    <category>
      <category>Electrolytes</category>
      <mesh-id>D004573</mesh-id>
    </category>
    <category>
      <category>Ions</category>
      <mesh-id>D007477</mesh-id>
    </category>
    <category>
      <category>Laxatives</category>
      <mesh-id>D054368</mesh-id>
    </category>
    <category>
      <category>Osmotic Laxatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phosphate salts</category>
      <mesh-id>D010710</mesh-id>
    </category>
    <category>
      <category>Phosphoric Acids</category>
      <mesh-id>D010756</mesh-id>
    </category>
    <category>
      <category>Phosphorus Acids</category>
      <mesh-id>D017976</mesh-id>
    </category>
    <category>
      <category>Phosphorus Compounds</category>
      <mesh-id>D017553</mesh-id>
    </category>
    <category>
      <category>Potassium Salt</category>
      <mesh-id/>
    </category>
    <category>
      <category>Urinary Acidifying Agents</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Unknown</route>
      <strength/>
    </dosage>
    <dosage>
      <form/>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Paste</form>
      <route>Dental</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intrathecal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Irrigation</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravesical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Extracorporeal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Enema</form>
      <route>Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Respiratory (inhalation)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, sugar coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09449.pdf?1496442434</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09449.pdf?1496442434</msds>
  <patents>
    <patent>
      <number>7687075</number>
      <country>United States</country>
      <approved>2010-03-30</approved>
      <expires>2028-06-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7084130</number>
      <country>United States</country>
      <approved>2006-08-01</approved>
      <expires>2021-11-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Sodium phosphate, monobasic may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Sodium phosphate, monobasic may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tramadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Trospium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxyphenonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Benzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ipratropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Metixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Buclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Doxylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Trihexyphenidyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxyphencyclimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Procyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hyoscyamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Cyproheptadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methscopolamine bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Darifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tridihexethyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Anisotropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Atropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Pirenzepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Homatropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Clidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Propantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dicyclomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Brompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Cycrimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Revefenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Batefenterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The serum concentration of Amphetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The serum concentration of Phentermine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The serum concentration of Pseudoephedrine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The serum concentration of Benzphetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The serum concentration of Diethylpropion can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The serum concentration of Lisdexamfetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The serum concentration of Mephentermine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The serum concentration of MMDA can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The serum concentration of Midomafetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The serum concentration of Tenamfetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The serum concentration of Chlorphentermine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The serum concentration of Methylenedioxyethamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The serum concentration of Dextroamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The serum concentration of Metamfetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The serum concentration of Iofetamine I-123 can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The serum concentration of Ritobegron can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The serum concentration of Mephedrone can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The serum concentration of Methoxyphenamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The serum concentration of Gepefrine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Valsartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Olmesartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Losartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The risk or severity of nephrotoxicity can be increased when Candesartan cilexetil is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Eprosartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Telmisartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Irbesartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01342</drugbank-id>
      <name>Forasartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Forasartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Saprisartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01349</drugbank-id>
      <name>Tasosartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Tasosartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of nephrotoxicity can be increased when Saralasin is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>The risk or severity of nephrotoxicity can be increased when Azilsartan medoxomil is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Fimasartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The risk or severity of nephrotoxicity can be increased when Candesartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Ramipril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Fosinopril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Trandolapril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Benazepril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Enalapril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Moexipril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Lisinopril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Perindopril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Quinapril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of nephrotoxicity can be increased when Omapatrilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of nephrotoxicity can be increased when Rescinnamine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Captopril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Cilazapril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Spirapril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Temocapril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Imidapril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Zofenopril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>The risk or severity of nephrotoxicity can be increased when Delapril is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>The risk or severity of nephrotoxicity can be increased when Benazeprilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>The risk or severity of nephrotoxicity can be increased when Fosinoprilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>The risk or severity of nephrotoxicity can be increased when Ramiprilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14209</drugbank-id>
      <name>Trandolaprilat</name>
      <description>The risk or severity of nephrotoxicity can be increased when Trandolaprilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14210</drugbank-id>
      <name>Moexiprilat</name>
      <description>The risk or severity of nephrotoxicity can be increased when Moexiprilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>The risk or severity of nephrotoxicity can be increased when Perindoprilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>The risk or severity of nephrotoxicity can be increased when Quinaprilat is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>The risk or severity of nephrotoxicity can be increased when Quinoline Yellow WS is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>The risk or severity of nephrotoxicity can be increased when Sodium phosphate, monobasic is combined with Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>The risk or severity of nephrotoxicity can be increased when Remikiren is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03395</drugbank-id>
      <name>Enalkiren</name>
      <description>The risk or severity of nephrotoxicity can be increased when Enalkiren is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12416</drugbank-id>
      <name>VTP-27999</name>
      <description>The risk or severity of nephrotoxicity can be increased when VTP-27999 is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Torasemide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Methyclothiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Chlorthalidone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>Ethoxzolamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Triamterene may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Spironolactone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Bendroflumethiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Metolazone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Benzthiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Amiloride may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Cyclothiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Furosemide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Eplerenone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>Methazolamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>Mannitol may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Hydroflumethiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Indapamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>Acetazolamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>Conivaptan may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Chlorothiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Bumetanide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>Etacrynic acid may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Zonisamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Hydrochlorothiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Trichlormethiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Diazoxide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Diclofenamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Polythiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Quinethazone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Drospirenone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>Theobromine may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Piretanide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>Tienilic acid may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05034</drugbank-id>
      <name>Ularitide</name>
      <description>Ularitide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>Tolvaptan may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>Dapagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>Indisulam may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Canagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>Azosemide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>Canrenoic acid may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Empagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>Potassium citrate may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Efonidipine may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>Mersalyl may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>Isosorbide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>Ertugliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>Canrenone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12670</drugbank-id>
      <name>Rolofylline</name>
      <description>Rolofylline may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12704</drugbank-id>
      <name>Spiradoline</name>
      <description>Spiradoline may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>Cicletanine may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>Meticrane may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>Ibopamine may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>Mefruside may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>Mebutizide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Cyclopenthiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>Clorexolone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>Clofenamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>Fenquizone may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>Clopamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>Muzolimine may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Xipamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Epitizide may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>Bromotheophylline may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>Potassium may increase the nephrotoxic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>Calcium acetate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00326</drugbank-id>
      <name>Calcium glucoheptonate</name>
      <description>Calcium glucoheptonate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>Calcium can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>Calcium carbonate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>Calcium Citrate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>Calcium gluconate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>Calcium Phosphate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13142</drugbank-id>
      <name>Calcium glubionate anhydrous</name>
      <description>Calcium glubionate anhydrous can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13231</drugbank-id>
      <name>Calcium lactate</name>
      <description>Calcium lactate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13365</drugbank-id>
      <name>Calcium lactate gluconate</name>
      <description>Calcium lactate gluconate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13590</drugbank-id>
      <name>Calcium pangamate</name>
      <description>Calcium pangamate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>Calcium cation can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>Calcium polycarbophil can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The risk or severity of seizure can be increased when Amitriptyline is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of seizure can be increased when Protriptyline is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of seizure can be increased when Imipramine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of seizure can be increased when Nortriptyline is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of seizure can be increased when Amoxapine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of seizure can be increased when Trimipramine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The risk or severity of seizure can be increased when Doxepin is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of seizure can be increased when Desipramine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of seizure can be increased when Clomipramine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The risk or severity of seizure can be increased when Amineptine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>The risk or severity of seizure can be increased when Dimetacrine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of seizure can be increased when Butriptyline is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The risk or severity of seizure can be increased when Dosulepin is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of seizure can be increased when Tianeptine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>The risk or severity of seizure can be increased when Oxaprotiline is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The risk or severity of seizure can be increased when Opipramol is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The risk or severity of seizure can be increased when Amitriptylinoxide is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The risk or severity of seizure can be increased when Dibenzepin is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>The risk or severity of seizure can be increased when Quinupramine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The risk or severity of seizure can be increased when Melitracen is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The risk or severity of seizure can be increased when Lofepramine is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The risk or severity of seizure can be increased when Iprindole is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>The risk or severity of seizure can be increased when Imipramine oxide is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Icosapent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ketorolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Licofelone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Polmacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Flurbiprofen axetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>Sucralfate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>Magaldrate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>Hydrotalcite can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13359</drugbank-id>
      <name>Magnesium aspartate</name>
      <description>Magnesium aspartate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13749</drugbank-id>
      <name>Magnesium gluconate</name>
      <description>Magnesium gluconate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13786</drugbank-id>
      <name>Magnesium orotate</name>
      <description>Magnesium orotate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14514</drugbank-id>
      <name>Magnesium levulinate</name>
      <description>Magnesium levulinate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14515</drugbank-id>
      <name>Magnesium lactate</name>
      <description>Magnesium lactate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>Magnesium citrate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>Sodium phosphate, monobasic can cause a decrease in the absorption of Magnesium resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>Aluminium can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>Magnesium oxide can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>Aluminum hydroxide can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Magnesium hydroxide can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Magnesium trisilicate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Magnesium carbonate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>Magnesium silicate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>Aluminium acetoacetate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>Magnesium peroxide can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>Aluminium glycinate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Xylometazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08162</drugbank-id>
      <name>Fasudil</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Fasudil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aloglutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Morphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Codeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hydromorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxycodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Butorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Pentazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Naltrexone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Fentanyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Nalbuphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Levorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Diphenoxylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxymorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dezocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methadyl acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dihydroetorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Diamorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Bezitramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ethylmorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Etorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dextromoramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Desomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Carfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dihydrocodeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Alphacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dihydromorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tapentadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ketobemidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with DPDPE.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Lofentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Eluxadoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Opium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Normethadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Piritramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Alphaprodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Nicomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Meptazinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Phenoperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Phenazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tilidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Carfentanil, C-11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15465</drugbank-id>
      <name>Benzhydrocodone</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Benzhydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Almasilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Calcium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00809</drugbank-id>
      <name>Tropicamide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hexafluronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00979</drugbank-id>
      <name>Cyclopentolate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Cyclopentolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Fenoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11181</drugbank-id>
      <name>Homatropine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Homatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Butabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Talbutal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Metocurine iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Dextromethorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Procaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Amantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Chloroprocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Butobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Heptabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01496</drugbank-id>
      <name>Barbituric acid derivative</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Barbituric acid derivative.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Gantacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Succinylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Nitrofurantoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Dantrolene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02968</drugbank-id>
      <name>Penicillin G Acyl-Serine</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Penicillin G Acyl-Serine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Ammonium chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Nicorandil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11098</drugbank-id>
      <name>Potassium bicarbonate</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Potassium bicarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12097</drugbank-id>
      <name>Mannitol busulfan</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Mannitol busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>Nicardipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>Trimebutine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>Otilonium may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Isradipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>Diltiazem may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>Amlodipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>Nimodipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>Nisoldipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>Lercanidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>Cinnarizine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>Loperamide may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>Felodipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>Nitrendipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>Perhexiline may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>Nifedipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>Amiodarone may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>Carvedilol may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>Bepridil may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>Mibefradil may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>Prenylamine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>Cyclandelate may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>Fluspirilene may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Clevidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>Seletracetam may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>Nylidrin may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>Ziconotide may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>Dotarizine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>Nilvadipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>Agmatine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>Fendiline may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>Eperisone may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>Pinaverium may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>Barnidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>Aranidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>Azelnidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>Benidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>Cilnidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>Darodipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Lacidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>Manidipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>Niguldipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>Niludipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>Carboxyamidotriazole may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Tetrahydropalmatine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>Gallopamil may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>Bencyclane may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>Terodiline may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>Lidoflazine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>Penfluridol may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>Caroverine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>WIN 55212-2 may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>Fish oil may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>Dexverapamil may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>Emopamil may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>Lomerizine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>Tetrandrine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>Dexniguldipine may increase the hyperkalemic activities of Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14498</drugbank-id>
      <name>Potassium acetate</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Potassium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00825</drugbank-id>
      <name>Levomenthol</name>
      <description>Sodium phosphate, monobasic may increase the hyperkalemic activities of Levomenthol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Trimethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ethosuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The therapeutic efficacy of Lorazepam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Butalbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The therapeutic efficacy of Phenytoin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The therapeutic efficacy of Valproic acid can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The therapeutic efficacy of Clobazam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The therapeutic efficacy of Secobarbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Metharbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The therapeutic efficacy of Methohexital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The therapeutic efficacy of Carbamazepine can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Thiopental can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The therapeutic efficacy of Paramethadione can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The therapeutic efficacy of Clorazepic acid can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The therapeutic efficacy of Tizanidine can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The therapeutic efficacy of Riluzole can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The therapeutic efficacy of Ethotoin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The therapeutic efficacy of Primidone can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The therapeutic efficacy of Diazepam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>The therapeutic efficacy of Phensuximide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>The therapeutic efficacy of Progabide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The therapeutic efficacy of Tiagabine can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The therapeutic efficacy of Felbamate can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The therapeutic efficacy of Zaleplon can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The therapeutic efficacy of Clonazepam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>The therapeutic efficacy of Phenacemide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The therapeutic efficacy of Thiamylal can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The therapeutic efficacy of Estazolam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Amobarbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Barbital can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The therapeutic efficacy of Delorazepam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>The therapeutic efficacy of Valpromide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The therapeutic efficacy of Ezogabine can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The therapeutic efficacy of Rufinamide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The therapeutic efficacy of Lacosamide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The therapeutic efficacy of Remacemide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The therapeutic efficacy of Deramciclane can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>The therapeutic efficacy of Tramiprosate can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>The therapeutic efficacy of Sulthiame can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The therapeutic efficacy of Perampanel can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>The therapeutic efficacy of Beclamide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The therapeutic efficacy of Stiripentol can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The therapeutic efficacy of Doramectin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The therapeutic efficacy of Tiletamine can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>The therapeutic efficacy of Brexanolone can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>The therapeutic efficacy of Etiracetam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>The therapeutic efficacy of Carisbamate can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>The therapeutic efficacy of Pheneturide can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The therapeutic efficacy of Medazepam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The therapeutic efficacy of Phenibut can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>The therapeutic efficacy of Ethadione can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>The therapeutic efficacy of Cannabidivarin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The therapeutic efficacy of Pregabalin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The therapeutic efficacy of Gabapentin can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The therapeutic efficacy of Topiramate can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The therapeutic efficacy of Cenobamate can be decreased when used in combination with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of seizure can be increased when Sodium phosphate, monobasic is combined with Amifampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>The risk or severity of adverse effects can be increased when Sorbitol is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04816</drugbank-id>
      <name>Dantron</name>
      <description>The risk or severity of adverse effects can be increased when Dantron is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04823</drugbank-id>
      <name>Oxyphenisatin</name>
      <description>The risk or severity of adverse effects can be increased when Oxyphenisatin is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09020</drugbank-id>
      <name>Bisacodyl</name>
      <description>The risk or severity of adverse effects can be increased when Bisacodyl is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The risk or severity of adverse effects can be increased when Picosulfuric acid is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09311</drugbank-id>
      <name>Polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Polycarbophil is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium sulfate is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11059</drugbank-id>
      <name>Carboxymethylcellulose</name>
      <description>The risk or severity of adverse effects can be increased when Carboxymethylcellulose is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11097</drugbank-id>
      <name>Plantago seed</name>
      <description>The risk or severity of adverse effects can be increased when Plantago seed is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11113</drugbank-id>
      <name>Castor oil</name>
      <description>The risk or severity of adverse effects can be increased when Castor oil is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11365</drugbank-id>
      <name>Sennosides</name>
      <description>The risk or severity of adverse effects can be increased when Sennosides is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12942</drugbank-id>
      <name>Lactitol</name>
      <description>The risk or severity of adverse effects can be increased when Lactitol is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The risk or severity of adverse effects can be increased when Lactulose is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The risk or severity of adverse effects can be increased when Glycerin is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11057</drugbank-id>
      <name>Mineral oil</name>
      <description>The risk or severity of adverse effects can be increased when Mineral oil is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11089</drugbank-id>
      <name>Docusate</name>
      <description>The risk or severity of adverse effects can be increased when Docusate is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11228</drugbank-id>
      <name>Methylcellulose</name>
      <description>The risk or severity of adverse effects can be increased when Methylcellulose is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13526</drugbank-id>
      <name>Pentaerithrityl</name>
      <description>The risk or severity of adverse effects can be increased when Pentaerithrityl is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13707</drugbank-id>
      <name>Sodium tartrate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium tartrate is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04824</drugbank-id>
      <name>Phenolphthalein</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Phenolphthalein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Bisoxatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Lubiprostone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08890</drugbank-id>
      <name>Linaclotide</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Linaclotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Prucalopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Tegaserod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13170</drugbank-id>
      <name>Plecanatide</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Plecanatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14232</drugbank-id>
      <name>Deacetylbisacodyl</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Deacetylbisacodyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Magnesium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01593</drugbank-id>
      <name>Zinc</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Zinc.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14516</drugbank-id>
      <name>Sodium cation</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Sodium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14546</drugbank-id>
      <name>Sulfate ion</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Sulfate ion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14585</drugbank-id>
      <name>Plantago ovata seed</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Plantago ovata seed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09269</drugbank-id>
      <name>Phenylacetic acid</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Phenylacetic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09409</drugbank-id>
      <name>Magnesium acetate tetrahydrate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Magnesium acetate tetrahydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09484</drugbank-id>
      <name>Sodium fluorophosphate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Sodium fluorophosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Magnesium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13180</drugbank-id>
      <name>Gluconic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Gluconic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13743</drugbank-id>
      <name>Sodium aurotiosulfate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Sodium aurotiosulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13996</drugbank-id>
      <name>Magnesium acetate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Magnesium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14482</drugbank-id>
      <name>Sodium ascorbate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Sodium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Potassium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14503</drugbank-id>
      <name>Sodium phosphate, monobasic, unspecified form</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Sodium phosphate, monobasic, unspecified form.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14627</drugbank-id>
      <name>Oxyphenisatin acetate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Oxyphenisatin acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07715</drugbank-id>
      <name>Emodin</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Emodin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14963</drugbank-id>
      <name>Konjac mannan</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Konjac mannan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15477</drugbank-id>
      <name>Alloin</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Alloin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15478</drugbank-id>
      <name>Frangula purshiana bark</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Frangula purshiana bark.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Dehydrocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>The risk or severity of seizure can be increased when Sodium phosphate, monobasic is combined with Dalfampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The risk or severity of seizure can be increased when Bupropion is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Nitroprusside can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00893</drugbank-id>
      <name>Iron Dextran</name>
      <description>Iron Dextran can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01592</drugbank-id>
      <name>Iron</name>
      <description>Iron can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06215</drugbank-id>
      <name>Ferumoxytol</name>
      <description>Ferumoxytol can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06783</drugbank-id>
      <name>Prussian blue</name>
      <description>Prussian blue can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08917</drugbank-id>
      <name>Ferric carboxymaltose</name>
      <description>Ferric carboxymaltose can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09146</drugbank-id>
      <name>Iron sucrose</name>
      <description>Iron sucrose can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09147</drugbank-id>
      <name>Ferric pyrophosphate</name>
      <description>Ferric pyrophosphate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09501</drugbank-id>
      <name>Ferric ammonium citrate</name>
      <description>Ferric ammonium citrate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09507</drugbank-id>
      <name>Ferumoxsil</name>
      <description>Ferumoxsil can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09508</drugbank-id>
      <name>Ferumoxides</name>
      <description>Ferumoxides can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11171</drugbank-id>
      <name>Ferric sulfate</name>
      <description>Ferric sulfate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11210</drugbank-id>
      <name>Ferrous bisglycinate</name>
      <description>Ferrous bisglycinate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11417</drugbank-id>
      <name>Gleptoferron</name>
      <description>Gleptoferron can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11576</drugbank-id>
      <name>Ferric oxide</name>
      <description>Ferric oxide can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12208</drugbank-id>
      <name>Iron isomaltoside 1000</name>
      <description>Iron isomaltoside 1000 can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12821</drugbank-id>
      <name>Perflubutane</name>
      <description>Perflubutane can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13257</drugbank-id>
      <name>Ferrous sulfate anhydrous</name>
      <description>Ferrous sulfate anhydrous can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13381</drugbank-id>
      <name>Sodium feredetate</name>
      <description>Sodium feredetate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13423</drugbank-id>
      <name>Ferric hydroxide</name>
      <description>Ferric hydroxide can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13569</drugbank-id>
      <name>Ferrous chloride</name>
      <description>Ferrous chloride can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13949</drugbank-id>
      <name>Ferric cation</name>
      <description>Ferric cation can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14488</drugbank-id>
      <name>Ferrous gluconate</name>
      <description>Ferrous gluconate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14489</drugbank-id>
      <name>Ferrous succinate</name>
      <description>Ferrous succinate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14491</drugbank-id>
      <name>Ferrous fumarate</name>
      <description>Ferrous fumarate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14520</drugbank-id>
      <name>Tetraferric tricitrate decahydrate</name>
      <description>Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14695</drugbank-id>
      <name>Ferric oxyhydroxide</name>
      <description>Ferric oxyhydroxide can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>sodium dihydrogen phosphate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>sodium dihydrogen phosphate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>119.977</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>119.958839739</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Na+].OP(O)([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>H2NaO4P</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>AJPJDKMHJJGVTQ-UHFFFAOYSA-M</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>80.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>13.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>5.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>121 g/L</value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>Decomposes at 75</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>293</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4753</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4759</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20445</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>37585</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>23672064</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827853</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>22626</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sodium_phosphates</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1368</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0005055</id>
      <name>Sodium-dependent phosphate transporter 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19450</ref-id>
            <pubmed-id>23398154</pubmed-id>
            <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q8WUM9" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transporter 1</name>
        <general-function/>
        <specific-function/>
        <gene-name>SLC20A1</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>73699.01</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10946</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8WUM9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S20A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Gibbon ape leukemia virus receptor 1</synonym>
          <synonym>GLVR-1</synonym>
          <synonym>GLVR1</synonym>
          <synonym>Leukemia virus receptor 1 homolog</synonym>
          <synonym>Phosphate transporter 1</synonym>
          <synonym>PiT-1</synonym>
          <synonym>PIT1</synonym>
          <synonym>Solute carrier family 20 member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0022118|Sodium-dependent phosphate transporter 1
MATLITSTTAATAASGPLVDYLWMLILGFIIAFVLAFSVGANDVANSFGTAVGSGVVTLK
QACILASIFETVGSVLLGAKVSETIRKGLIDVEMYNSTQGLLMAGSVSAMFGSAVWQLVA
SFLKLPISGTHCIVGATIGFSLVAKGQEGVKWSELIKIVMSWFVSPLLSGIMSGILFFLV
RAFILHKADPVPNGLRALPVFYACTVGINLFSIMYTGAPLLGFDKLPLWGTILISVGCAV
FCALIVWFFVCPRMKRKIEREIKCSPSESPLMEKKNSLKEDHEETKLSVGDIENKHPVSE
VGPATVPLQAVVEERTVSFKLGDLEEAPERERLPSVDLKEETSIDSTVNGAVQLPNGNLV
QFSQAVSNQINSSGHYQYHTVHKDSGLYKELLHKLHLAKVGDCMGDSGDKPLRRNNSYTS
YTMAICGMPLDSFRAKEGEQKGEEMEKLTWPNADSKKRIRMDSYTSYCNAVSDLHSASEI
DMSVKAEMGLGDRKGSNGSLEEWYDQDKPEVSLLFQFLQILTACFGSFAHGGNDVSNAIG
PLVALYLVYDTGDVSSKVATPIWLLLYGGVGICVGLWVWGRRVIQTMGKDLTPITPSSGF
SIELASALTVVIASNIGLPISTTHCKVGSVVSVGWLRSKKAVDWRLFRNIFMAWFVTVPI
SGVISAAIMAIFRYVILRM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0022119|Sodium-dependent phosphate transporter 1 (SLC20A1)
ATGGCAACGCTGATTACCAGTACTACAGCTGCTACCGCCGCTTCTGGTCCTTTGGTGGAC
TACCTATGGATGCTCATCCTGGGCTTCATTATTGCATTTGTCTTGGCATTCTCCGTGGGA
GCCAATGATGTAGCAAATTCTTTTGGTACAGCTGTGGGCTCAGGTGTAGTGACCCTGAAG
CAAGCCTGCATCCTAGCTAGCATCTTTGAAACAGTGGGCTCTGTCTTACTGGGGGCCAAA
GTGAGCGAAACCATCCGGAAGGGCTTGATTGACGTGGAGATGTACAACTCGACTCAAGGG
CTGCTGATGGCCGGCTCAGTCAGTGCTATGTTTGGTTCTGCTGTGTGGCAACTCGTGGCT
TCGTTTTTGAAGCTCCCTATTTCTGGAACCCATTGTATTGTTGGTGCAACTATTGGTTTC
TCCCTCGTGGCAAAGGGGCAGGAGGGTGTCAAGTGGTCTGAACTGATAAAAATTGTGATG
TCTTGGTTCGTGTCCCCACTGCTTTCTGGAATTATGTCTGGAATTTTATTCTTCCTGGTT
CGTGCATTCATCCTCCATAAGGCAGATCCAGTTCCTAATGGTTTGCGAGCTTTGCCAGTT
TTCTATGCCTGCACAGTTGGAATAAACCTCTTTTCCATCATGTATACTGGAGCACCGTTG
CTGGGCTTTGACAAACTTCCTCTGTGGGGTACCATCCTCATCTCGGTGGGATGTGCAGTT
TTCTGTGCCCTTATCGTCTGGTTCTTTGTATGTCCCAGGATGAAGAGAAAAATTGAACGA
GAAATAAAGTGTAGTCCTTCTGAAAGCCCCTTAATGGAAAAAAAGAATAGCTTGAAAGAA
GACCATGAAGAAACAAAGTTGTCTGTTGGTGATATTGAAAACAAGCATCCTGTTTCTGAG
GTAGGGCCTGCCACTGTGCCCCTCCAGGCTGTGGTGGAGGAGAGAACAGTCTCATTCAAA
CTTGGAGATTTGGAGGAAGCTCCAGAGAGAGAGAGGCTTCCCAGCGTGGACTTGAAAGAG
GAAACCAGCATAGATAGCACCGTGAATGGTGCAGTGCAGTTGCCTAATGGGAACCTTGTC
CAGTTCAGTCAAGCCGTCAGCAACCAAATAAACTCCAGTGGCCACTACCAGTATCACACC
GTGCATAAGGATTCCGGCCTGTACAAAGAGCTACTCCATAAATTACATCTTGCCAAGGTG
GGAGATTGCATGGGAGACTCCGGTGACAAACCCTTAAGGCGCAATAATAGCTATACTTCC
TATACCATGGCAATATGTGGCATGCCTCTGGATTCATTCCGTGCCAAAGAAGGTGAACAG
AAGGGCGAAGAAATGGAGAAGCTGACATGGCCTAATGCAGACTCCAAGAAGCGAATTCGA
ATGGACAGTTACACCAGTTACTGCAATGCTGTGTCTGACCTTCACTCAGCATCTGAGATA
GACATGAGTGTCAAGGCAGAGATGGGTCTAGGTGACAGAAAAGGAAGTAATGGCTCTCTA
GAAGAATGGTATGACCAGGATAAGCCTGAAGTCTCTCTCCTCTTCCAGTTCCTGCAGATC
CTTACAGCCTGCTTTGGGTCATTCGCCCATGGTGGCAATGACGTAAGCAATGCCATTGGG
CCTCTGGTTGCTTTATATTTGGTTTATGACACAGGAGATGTTTCTTCAAAAGTGGCAACA
CCAATATGGCTTCTACTCTATGGTGGTGTTGGTATCTGTGTTGGTCTGTGGGTTTGGGGA
AGAAGAGTTATCCAGACCATGGGGAAGGATCTGACACCGATCACACCCTCTAGTGGCTTC
AGTATTGAACTGGCATCTGCCCTCACTGTGGTGATTGCATCAAATATTGGCCTTCCCATC
AGTACAACACATTGTAAAGTGGGCTCTGTTGTGTCTGTTGGCTGGCTCCGGTCCAAGAAG
GCTGTTGACTGGCGTCTCTTTCGTAACATTTTTATGGCCTGGTTTGTCACAGTCCCCATT
TCTGGAGTTATCAGTGCTGCCATCATGGCAATCTTCAGATATGTCATCCTCAGAATGTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01384</identifier>
            <name>PHO4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high-affinity inorganic phosphate</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>signal transducer activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0008680</id>
      <name>Sodium-dependent phosphate transporter 2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19450</ref-id>
            <pubmed-id>23398154</pubmed-id>
            <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q08357" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transporter 2</name>
        <general-function>Virus receptor activity</general-function>
        <specific-function>Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular metabolism, signal transduction, and nucleic acid and lipid synthesis. In vitro, sodium-dependent phosphate uptake is not siginificantly affected by acidic and alkaline conditions, however sodium-independent phosphate uptake occurs at acidic conditions. May play a role in extracellular matrix, cartilage and vascular calcification. Functions as a retroviral receptor and confers human cells susceptibility to infection to amphotropic murine leukemia virus (A-MuLV), 10A1 murine leukemia virus (10A1 MLV) and some feline leukemia virus subgroup B (FeLV-B) variants.</specific-function>
        <gene-name>SLC20A2</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>6-26
47-67
87-107
110-130
143-163
191-211
214-234
483-503
531-551
572-586
594-609
622-642</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>70391.755</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10947</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q08357</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S20A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Gibbon ape leukemia virus receptor 2</synonym>
          <synonym>GLVR-2</synonym>
          <synonym>GLVR2</synonym>
          <synonym>hPit2</synonym>
          <synonym>Phosphate transporter 2</synonym>
          <synonym>PiT-2</synonym>
          <synonym>PIT2</synonym>
          <synonym>Solute carrier family 20 member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049436|Sodium-dependent phosphate transporter 2
MAMDEYLWMVILGFIIAFILAFSVGANDVANSFGTAVGSGVVTLRQACILASIFETTGSV
LLGAKVGETIRKGIIDVNLYNETVETLMAGEVSAMVGSAVWQLIASFLRLPISGTHCIVG
STIGFSLVAIGTKGVQWMELVKIVASWFISPLLSGFMSGLLFVLIRIFILKKEDPVPNGL
RALPVFYAATIAINVFSIMYTGAPVLGLVLPMWAIALISFGVALLFAFFVWLFVCPWMRR
KITGKLQKEGALSRVSDESLSKVQEAESPVFKELPGAKANDDSTIPLTGAAGETLGTSEG
TSAGSHPRAAYGRALSMTHGSVKSPISNGTFGFDGHTRSDGHVYHTVHKDSGLYKDLLHK
IHIDRGPEEKPAQESNYRLLRRNNSYTCYTAAICGLPVHATFRAADSSAPEDSEKLVGDT
VSYSKKRLRYDSYSSYCNAVAEAEIEAEEGGVEMKLASELADPDQPREDPAEEEKEEKDA
PEVHLLFHFLQVLTACFGSFAHGGNDVSNAIGPLVALWLIYKQGGVTQEAATPVWLLFYG
GVGICTGLWVWGRRVIQTMGKDLTPITPSSGFTIELASAFTVVIASNIGLPVSTTHCKVG
SVVAVGWIRSRKAVDWRLFRNIFVAWFVTVPVAGLFSAAVMALLMYGILPYV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049437|Sodium-dependent phosphate transporter 2 (SLC20A2)
ATGGCCATGGATGAGTATTTGTGGATGGTCATTTTGGGTTTCATCATAGCTTTCATCTTG
GCCTTTTCTGTTGGTGCAAACGATGTTGCCAACTCCTTTGGTACAGCCGTGGGCTCTGGT
GTGGTGACCTTGAGGCAGGCATGCATTTTAGCTTCAATATTTGAAACCACCGGCTCCGTG
TTACTAGGCGCCAAAGTAGGAGAAACCATTCGCAAAGGTATCATTGACGTGAACCTGTAC
AACGAGACGGTGGAGACTCTCATGGCTGGGGAAGTTAGTGCCATGGTTGGTTCCGCTGTG
TGGCAGCTGATTGCTTCCTTCCTGAGGCTTCCAATCTCAGGAACGCACTGCATTGTGGGT
TCTACTATAGGATTCTCACTGGTCGCAATCGGTACCAAAGGTGTGCAGTGGATGGAGCTT
GTCAAGATTGTTGCTTCTTGGTTTATATCTCCACTGTTGTCTGGTTTCATGTCTGGCCTG
CTGTTTGTACTCATCAGAATTTTCATCTTAAAAAAGGAAGACCCTGTTCCCAATGGCCTC
CGGGCACTCCCAGTATTCTATGCTGCTACCATAGCAATCAATGTCTTTTCCATCATGTAC
ACAGGAGCACCAGTGCTCGGCCTTGTTCTCCCCATGTGGGCCATAGCCCTCATTTCCTTT
GGTGTCGCCCTCCTGTTCGCTTTTTTTGTGTGGCTCTTCGTGTGTCCGTGGATGCGGAGG
AAAATAACAGGCAAATTACAAAAAGAAGGTGCTTTATCACGAGTATCTGACGAAAGCCTC
AGTAAGGTTCAGGAAGCAGAGTCCCCAGTATTTAAAGAGCTACCAGGTGCCAAGGCTAAT
GATGACAGCACCATCCCGCTCACGGGAGCAGCAGGGGAGACACTGGGGACCTCGGAAGGC
ACTTCTGCGGGCAGCCACCCTCGGGCTGCATACGGAAGAGCACTGTCCATGACCCATGGC
TCTGTGAAATCGCCCATCTCCAACGGCACCTTCGGCTTCGACGGCCACACCAGGAGCGAC
GGTCATGTGTACCACACCGTGCACAAAGACTCGGGGCTCTACAAAGATCTGCTGCACAAA
ATCCACATCGACAGGGGCCCCGAGGAGAAGCCAGCCCAGGAAAGCAACTACCGGCTGCTG
CGCCGAAACAACAGTTACACCTGCTACACCGCAGCCATTTGTGGGCTGCCAGTGCACGCC
ACCTTTCGAGCTGCGGACTCATCGGCCCCAGAGGACAGTGAGAAGCTGGTGGGCGACACC
GTGTCCTACTCCAAGAAGAGGCTGCGCTACGACAGCTACTCGAGCTACTGTAACGCGGTG
GCAGAGGCGGAGATCGAGGCGGAGGAGGGCGGCGTGGAGATGAAGCTGGCGTCGGAGCTG
GCCGACCCTGACCAGCCGCGAGAGGACCCTGCAGAGGAGGAGAAGGAGGAGAAGGACGCA
CCCGAGGTTCACCTCCTGTTCCATTTCCTGCAGGTCCTCACCGCCTGTTTCGGGTCCTTT
GCTCACGGCGGCAATGACGTGAGTAATGCCATCGGTCCCCTGGTAGCCTTGTGGCTGATT
TACAAACAAGGCGGGGTAACGCAAGAAGCAGCTACACCCGTCTGGCTGCTGTTTTATGGA
GGAGTTGGAATCTGCACAGGCCTCTGGGTCTGGGGGAGAAGAGTGATCCAGACCATGGGG
AAGGACCTCACTCCCATCACGCCGTCCAGCGGCTTCACGATCGAGCTGGCCTCAGCCTTC
ACAGTGGTGATCGCCTCCAACATCGGGCTTCCAGTCAGCACCACGCACTGTAAGGTGGGC
TCGGTGGTGGCCGTGGGCTGGATCCGCTCCCGCAAGGCTGTGGACTGGCGCCTCTTTCGG
AACATCTTCGTGGCCTGGTTCGTGACCGTCCCTGTGGCTGGGCTGTTCAGCGCTGCTGTC
ATGGCTCTTCTCATGTATGGGATCCTTCCATATGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01384</identifier>
            <name>PHO4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-dependent phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>virus receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0008681</id>
      <name>Sodium-dependent phosphate transport protein 2A</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19450</ref-id>
            <pubmed-id>23398154</pubmed-id>
            <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q06495" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transport protein 2A</name>
        <general-function>Sodium:phosphate symporter activity</general-function>
        <specific-function>Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.</specific-function>
        <gene-name>SLC34A1</gene-name>
        <locus/>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions>104-125
146-163
166-185
348-370
413-436
467-487
514-534
540-561</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>68936.53</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11019</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q06495</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NPT2A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Na(+)-dependent phosphate cotransporter 2A</synonym>
          <synonym>Na(+)/Pi cotransporter 2A</synonym>
          <synonym>NaPi-2a</synonym>
          <synonym>NaPi-3</synonym>
          <synonym>NPT2</synonym>
          <synonym>SLC17A2</synonym>
          <synonym>Sodium-phosphate transport protein 2A</synonym>
          <synonym>Sodium/phosphate cotransporter 2A</synonym>
          <synonym>Solute carrier family 34 member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049438|Sodium-dependent phosphate transport protein 2A
MLSYGERLGSPAVSPLPVRGGHVMRGTAFAYVPSPQVLHRIPGTSAYAFPSLGPVALAEH
TCPCGEVLERHEPLPAKLALEEEQKPESRLVPKLRQAGAMLLKVPLMLTFLYLFVCSLDM
LSSAFQLAGGKVAGDIFKDNAILSNPVAGLVVGILVTVLVQSSSTSTSIIVSMVSSGLLE
VSSAIPIIMGSNIGTSVTNTIVALMQAGDRTDFRRAFAGATVHDCFNWLSVLVLLPLEAA
TGYLHHITRLVVASFNIHGGRDAPDLLKIITEPFTKLIIQLDESVITSIATGDESLRNHS
LIQIWCHPDSLQAPTSMSRAEANSSQTLGNATMEKCNHIFVDTGLPDLAVGLILLAGSLV
LLCTCLILLVKMLNSLLKGQVAKVIQKVINTDFPAPFTWVTGYFAMVVGASMTFVVQSSS
VFTSAITPLIGLGVISIERAYPLTLGSNIGTTTTAILAALASPREKLSSAFQIALCHFFF
NISGILLWYPVPCTRLPIRMAKALGKRTAKYRWFAVLYLLVCFLLLPSLVFGISMAGWQV
MVGVGTPFGALLAFVVLINVLQSRSPGHLPKWLQTWDFLPRWMHSLKPLDHLITRATLCC
ARPEPRSPPLPPRVFLEELPPATPSPRLALPAHHNATRL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049439|Sodium-dependent phosphate transport protein 2A (SLC34A1)
ATGTTGTCCTACGGAGAGAGGCTGGGGTCCCCTGCTGTCTCCCCACTCCCAGTCCGTGGG
GGGCATGTGATGCGAGGGACGGCCTTTGCCTACGTGCCCAGCCCTCAGGTCCTACACAGG
ATCCCGGGGACCTCTGCCTATGCCTTCCCCAGCCTGGGCCCTGTGGCCCTTGCTGAGCAC
ACCTGCCCCTGTGGGGAGGTCCTGGAGCGCCATGAACCACTGCCTGCCAAGCTGGCCCTG
GAGGAGGAGCAGAAGCCAGAGTCCAGGCTGGTCCCCAAGCTGCGCCAGGCTGGCGCCATG
CTGCTCAAGGTGCCACTGATGCTCACCTTCCTCTACCTCTTCGTCTGCTCCCTGGACATG
CTCAGCTCGGCCTTCCAGCTGGCTGGAGGGAAGGTGGCTGGTGACATCTTCAAGGATAAC
GCCATCCTGTCCAACCCGGTGGCCGGGCTGGTGGTGGGGATCCTGGTGACCGTGCTGGTG
CAGAGCTCCAGCACCTCCACATCCATCATCGTCAGCATGGTCTCCTCTGGCTTGCTGGAG
GTGAGCTCTGCCATCCCCATCATCATGGGCTCCAACATCGGCACCTCTGTCACCAACACC
ATCGTGGCCCTGATGCAGGCGGGGGACAGGACTGACTTCCGGCGGGCCTTCGCGGGGGCC
ACGGTGCATGACTGCTTTAACTGGCTGTCAGTGCTGGTCCTGCTGCCCCTGGAGGCTGCC
ACTGGCTACCTGCACCACATCACTCGACTTGTGGTGGCCTCCTTCAACATCCATGGTGGC
CGTGATGCTCCTGACCTGCTCAAGATCATCACAGAGCCCTTCACGAAGCTCATCATCCAG
CTGGACGAGTCTGTGATAACCAGCATTGCCACTGGTGATGAGTCCCTGAGGAACCACAGT
CTCATCCAGATCTGGTGCCACCCAGACTCCTTACAGGCTCCCACCTCCATGTCCAGAGCA
GAGGCCAACTCCAGCCAGACCCTTGGAAATGCCACCATGGAGAAATGCAACCACATCTTT
GTGGACACTGGCCTACCGGACCTGGCTGTGGGGCTCATCCTGCTGGCAGGATCCCTGGTG
CTGCTGTGCACCTGCCTCATCCTCCTAGTCAAGATGCTCAACTCCCTGCTCAAGGGCCAA
GTGGCCAAGGTCATCCAGAAGGTCATCAATACGGACTTCCCTGCCCCCTTCACCTGGGTC
ACAGGCTACTTTGCCATGGTGGTGGGCGCCAGCATGACCTTCGTGGTCCAGAGCAGTTCT
GTGTTCACCTCGGCCATCACCCCACTCATCGGTCTTGGTGTGATCAGCATTGAGAGGGCC
TACCCGCTCACACTGGGTTCCAACATCGGCACCACCACCACGGCCATCCTGGCTGCCCTG
GCCAGCCCCAGGGAGAAGCTGTCCAGCGCTTTCCAGATTGCCCTCTGTCACTTCTTCTTC
AACATCTCGGGTATCCTTCTGTGGTACCCGGTGCCCTGCACACGCCTGCCCATCCGCATG
GCCAAGGCGCTGGGGAAACGCACGGCCAAGTACCGCTGGTTTGCCGTCCTCTATCTCCTT
GTCTGCTTCCTGCTGCTGCCCTCACTGGTGTTTGGCATCTCCATGGCAGGCTGGCAGGTC
ATGGTAGGTGTGGGCACGCCCTTCGGGGCCCTGCTGGCCTTCGTGGTGCTCATCAATGTC
CTGCAGAGTCGGAGTCCCGGGCACCTGCCCAAGTGGTTACAGACATGGGACTTCCTGCCT
CGCTGGATGCACTCCCTGAAGCCCCTGGACCACCTCATCACCCGCGCCACCCTATGCTGT
GCCAGGCCTGAGCCCCGCTCACCCCCGCTGCCCCCCAGGGTCTTCCTGGAGGAGCTACCC
CCTGCCACACCCTCCCCCCGTCTTGCACTGCCTGCTCACCACAATGCCACCCGCCTCTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02690</identifier>
            <name>Na_Pi_cotrans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PDZ domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein complex binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-dependent phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arsenate ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular phosphate ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to metal ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to parathyroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to staurosporine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dentinogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gentamycin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>indole metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>kidney development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ossification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphate transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sodium-dependent phosphate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to growth hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lead ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to magnesium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to mercury ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to potassium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to thyroid hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tricarboxylic acid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0008682</id>
      <name>Sodium-dependent phosphate transport protein 2B</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19450</ref-id>
            <pubmed-id>23398154</pubmed-id>
            <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="O95436" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transport protein 2B</name>
        <general-function>Sodium:phosphate symporter activity</general-function>
        <specific-function>May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli.</specific-function>
        <gene-name>SLC34A2</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>101-121
136-156
213-233
363-383
408-428
486-506
526-546
553-573</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>75758.535</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11020</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95436</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NPT2B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Na(+)-dependent phosphate cotransporter 2B</synonym>
          <synonym>Na(+)/Pi cotransporter 2B</synonym>
          <synonym>NaPi-2b</synonym>
          <synonym>NaPi3b</synonym>
          <synonym>Sodium-phosphate transport protein 2B</synonym>
          <synonym>Sodium/phosphate cotransporter 2B</synonym>
          <synonym>Solute carrier family 34 member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049440|Sodium-dependent phosphate transport protein 2B
MAPWPELGDAQPNPDKYLEGAAGQQPTAPDKSKETNKTDNTEAPVTKIELLPSYSTATLI
DEPTEVDDPWNLPTLQDSGIKWSERDTKGKILCFFQGIGRLILLLGFLYFFVCSLDILSS
AFQLVGGKMAGQFFSNSSIMSNPLLGLVIGVLVTVLVQSSSTSTSIVVSMVSSSLLTVRA
AIPIIMGANIGTSITNTIVALMQVGDRSEFRRAFAGATVHDFFNWLSVLVLLPVEVATHY
LEIITQLIVESFHFKNGEDAPDLLKVITKPFTKLIVQLDKKVISQIAMNDEKAKNKSLVK
IWCKTFTNKTQINVTVPSTANCTSPSLCWTDGIQNWTMKNVTYKENIAKCQHIFVNFHLP
DLAVGTILLILSLLVLCGCLIMIVKILGSVLKGQVATVIKKTINTDFPFPFAWLTGYLAI
LVGAGMTFIVQSSSVFTSALTPLIGIGVITIERAYPLTLGSNIGTTTTAILAALASPGNA
LRSSLQIALCHFFFNISGILLWYPIPFTRLPIRMAKGLGNISAKYRWFAVFYLIIFFFLI
PLTVFGLSLAGWRVLVGVGVPVVFIIILVLCLRLLQSRCPRVLPKKLQNWNFLPLWMRSL
KPWDAVVSKFTGCFQMRCCCCCRVCCRACCLLCDCPKCCRCSKCCEDLEEAQEGQDVPVK
APETFDNITISREAQGEVPASDSKTECTAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049441|Sodium-dependent phosphate transport protein 2B (SLC34A2)
ATGGCTCCCTGGCCTGAATTGGGAGATGCCCAGCCCAACCCCGATAAGTACCTCGAAGGG
GCCGCAGGTCAGCAGCCCACTGCCCCTGATAAAAGCAAAGAGACCAACAAAACAGATAAC
ACTGAGGCACCTGTAACCAAGATTGAACTTCTGCCGTCCTACTCCACGGCTACACTGATA
GATGAGCCCACTGAGGTGGATGACCCCTGGAACCTACCCACTCTTCAGGACTCGGGGATC
AAGTGGTCAGAGAGAGACACCAAAGGGAAGATTCTCTGTTTCTTCCAAGGGATTGGGAGA
TTGATTTTACTTCTCGGATTTCTCTACTTTTTCGTGTGCTCCCTGGATATTCTTAGTAGC
GCCTTCCAGCTGGTTGGAGGAAAAATGGCAGGACAGTTCTTCAGCAACAGCTCTATTATG
TCCAACCCTTTGTTGGGGCTGGTGATCGGGGTGCTGGTGACCGTCTTGGTGCAGAGCTCC
AGCACCTCAACGTCCATCGTTGTCAGCATGGTGTCCTCTTCATTGCTCACTGTTCGGGCT
GCCATCCCCATTATCATGGGGGCCAACATTGGAACGTCAATCACCAACACTATTGTTGCG
CTCATGCAGGTGGGAGATCGGAGTGAGTTCAGAAGAGCTTTTGCAGGAGCCACTGTCCAT
GACTTCTTCAACTGGCTGTCCGTGTTGGTGCTCTTGCCCGTGGAGGTGGCCACCCATTAC
CTCGAGATCATAACCCAGCTTATAGTGGAGAGCTTCCACTTCAAGAATGGAGAAGATGCC
CCAGATCTTCTGAAAGTCATCACTAAGCCCTTCACAAAGCTCATTGTCCAGCTGGATAAA
AAAGTTATCAGCCAAATTGCAATGAACGATGAAAAAGCGAAAAACAAGAGTCTTGTCAAG
ATTTGGTGCAAAACTTTTACCAACAAGACCCAGATTAACGTCACTGTTCCCTCGACTGCT
AACTGCACCTCCCCTTCCCTCTGTTGGACGGATGGCATCCAAAACTGGACCATGAAGAAT
GTGACCTACAAGGAGAACATCGCCAAATGCCAGCATATCTTTGTGAATTTCCACCTCCCG
GATCTTGCTGTGGGCACCATCTTGCTCATACTCTCCCTGCTGGTCCTCTGTGGTTGCCTG
ATCATGATTGTCAAGATCCTGGGCTCTGTGCTCAAGGGGCAGGTCGCCACTGTCATCAAG
AAGACCATCAACACTGATTTCCCCTTTCCCTTTGCATGGTTGACTGGCTACCTGGCCATC
CTCGTCGGGGCAGGCATGACCTTCATCGTACAGAGCAGCTCTGTGTTCACGTCGGCCTTG
ACCCCCCTGATTGGAATCGGCGTGATAACCATTGAGAGGGCTTATCCACTCACGCTGGGC
TCCAACATCGGCACCACCACCACCGCCATCCTGGCCGCCTTAGCCAGCCCTGGCAATGCA
TTGAGGAGTTCACTCCAGATCGCCCTGTGCCACTTTTTCTTCAACATCTCCGGCATCTTG
CTGTGGTACCCGATCCCGTTCACTCGCCTGCCCATCCGCATGGCCAAGGGGCTGGGCAAC
ATCTCTGCCAAGTATCGCTGGTTCGCCGTCTTCTACCTGATCATCTTCTTCTTCCTGATC
CCGCTGACGGTGTTTGGCCTCTCGCTGGCCGGCTGGCGGGTGCTGGTTGGTGTCGGGGTT
CCCGTCGTCTTCATCATCATCCTGGTACTGTGCCTCCGACTCCTGCAGTCTCGCTGCCCA
CGCGTCCTGCCGAAGAAACTCCAGAACTGGAACTTCCTGCCGCTGTGGATGCGCTCGCTG
AAGCCCTGGGATGCCGTCGTCTCCAAGTTCACCGGCTGCTTCCAGATGCGCTGCTGCTGC
TGCTGCCGCGTGTGCTGCCGCGCGTGCTGCTTGCTGTGTGGCTGCCCCAAGTGCTGCCGC
TGCAGCAAGTGCTGCGAGGACTTGGAGGAGGCGCAGGAGGGGCAGGATGTCCCTGTCAAG
GCTCCTGAGACCTTTGATAACATAACCATTAGCAGAGAGGCTCAGGGTGAGGTCCCTGCC
TCGGACTCAAAGACCGAATGCACGGCCTTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02690</identifier>
            <name>Na_Pi_cotrans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphate ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-dependent phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular phosphate ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="5">
      <id>BE0008683</id>
      <name>Sodium-dependent phosphate transport protein 2C</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1950</ref-id>
            <pubmed-id>12360109</pubmed-id>
            <citation>Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q8N130" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transport protein 2C</name>
        <general-function>Sodium:phosphate symporter activity</general-function>
        <specific-function>May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.</specific-function>
        <gene-name>SLC34A3</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>77-97
112-132
189-209
323-343
368-388
446-466
486-506
511-531</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>63548.94</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:20305</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8N130</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NPT2C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Na(+)-dependent phosphate cotransporter 2C</synonym>
          <synonym>Na(+)/Pi cotransporter 2C</synonym>
          <synonym>NaPi-2c</synonym>
          <synonym>NPT2C</synonym>
          <synonym>NPTIIC</synonym>
          <synonym>Sodium-phosphate transport protein 2C</synonym>
          <synonym>Sodium/inorganic phosphate cotransporter IIC</synonym>
          <synonym>Sodium/phosphate cotransporter 2C</synonym>
          <synonym>Solute carrier family 34 member 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049442|Sodium-dependent phosphate transport protein 2C
MPSSLPGSQVPHPTLDAVDLVEKTLRNEGTSSSAPVLEEGDTDPWTLPQLKDTSQPWKEL
RVAGRLRRVAGSVLKACGLLGSLYFFICSLDVLSSAFQLLGSKVAGDIFKDNVVLSNPVA
GLVIGVLVTALVQSSSTSSSIVVSMVAAKLLTVRVSVPIIMGVNVGTSITSTLVSMAQSG
DRDEFQRAFSGSAVHGIFNWLTVLVLLPLESATALLERLSELALGAASLTPRAQAPDILK
VLTKPLTHLIVQLDSDMIMSSATGNATNSSLIKHWCGTTGQPTQENSSCGAFGPCTEKNS
TAPADRLPCRHLFAGTELTDLAVGCILLAGSLLVLCGCLVLIVKLLNSVLRGRVAQVVRT
VINADFPFPLGWLGGYLAVLAGAGLTFALQSSSVFTAAVVPLMGVGVISLDRAYPLLLGS
NIGTTTTALLAALASPADRMLSALQVALIHFFFNLAGILLWYLVPALRLPIPLARHFGVV
TARYRWVAGVYLLLGFLLLPLAAFGLSLAGGMELAAVGGPLVGLVLLVILVTVLQRRRPA
WLPVRLRSWAWLPVWLHSLEPWDRLVTRCCPCNVCSPPKATTKEAYCYENPEILASQQL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049443|Sodium-dependent phosphate transport protein 2C (SLC34A3)
ATGCCGAGTTCCCTTCCCGGCAGCCAGGTCCCCCACCCCACTCTGGACGCGGTTGACCTA
GTGGAAAAGACTCTGAGGAATGAAGGGACCTCCAGTTCTGCTCCAGTCTTGGAGGAAGGG
GACACAGACCCCTGGACCCTCCCTCAGCTGAAGGACACAAGCCAGCCCTGGAAAGAGCTC
CGCGTGGCCGGCAGGCTGCGCCGCGTGGCCGGCAGCGTCCTCAAGGCCTGCGGGCTCCTC
GGCAGCCTGTACTTCTTCATCTGCTCTCTGGACGTCCTCAGCTCCGCCTTCCAGCTGCTG
GGCAGCAAAGTGGCCGGAGACATCTTCAAGGACAACGTGGTGCTGTCCAACCCTGTGGCT
GGACTGGTCATTGGCGTGCTGGTCACAGCCCTGGTGCAGAGTTCCAGCACGTCCTCCTCC
ATCGTGGTCAGCATGGTGGCTGCTAAGCTGCTGACTGTCCGGGTGTCTGTGCCCATCATC
ATGGGTGTCAACGTAGGCACATCCATCACCAGCACCCTGGTCTCAATGGCGCAGTCAGGG
GACCGGGATGAATTTCAGAGGGCTTTCAGCGGCTCGGCGGTGCACGGGATCTTCAACTGG
CTCACAGTGCTGGTCCTGCTGCCACTGGAGAGCGCCACGGCCCTGCTGGAGAGGCTAAGT
GAGCTAGCCCTGGGTGCCGCCAGCCTGACACCCAGGGCGCAGGCGCCCGACATCCTCAAG
GTGCTGACGAAGCCGCTCACACACCTCATCGTGCAGTTGGACTCCGACATGATCATGAGC
AGTGCCACAGGCAACGCCACTAACAGCAGTCTCATTAAGCACTGGTGCGGCACCACGGGG
CAGCCGACCCAGGAGAACAGCAGCTGTGGCGCCTTCGGCCCGTGCACAGAGAAGAACAGC
ACAGCCCCGGCGGACAGGCTGCCCTGCCGCCACCTGTTTGCGGGCACGGAGCTCACGGAC
CTGGCCGTGGGCTGCATCCTGCTGGCCGGCTCCCTGCTGGTGCTCTGCGGCTGCCTGGTC
CTCATAGTCAAGCTGCTCAACTCTGTGCTGCGCGGCCGCGTGGCCCAGGTCGTGAGGACA
GTCATCAATGCGGACTTCCCCTTCCCGCTGGGCTGGCTCGGCGGCTACCTGGCCGTCCTC
GCGGGCGCCGGCCTGACCTTCGCACTGCAGAGCAGCAGCGTCTTCACGGCGGCCGTCGTG
CCCCTCATGGGGGTCGGGGTGATCAGTCTGGACCGGGCGTACCCCCTCTTACTGGGCTCC
AACATCGGCACCACTACCACAGCCCTGCTGGCTGCCCTGGCCAGCCCCGCAGACAGGATG
CTCAGCGCCCTGCAGGTCGCCCTCATCCACTTCTTCTTCAACCTGGCCGGCATCCTGCTG
TGGTACCTGGTGCCTGCACTGCGGCTGCCCATCCCGCTGGCCAGGCACTTCGGGGTGGTG
ACCGCCCGTTACCGCTGGGTGGCTGGGGTCTACCTGCTGCTCGGATTCCTGCTGCTGCCC
CTGGCGGCCTTCGGGCTCTCCCTGGCAGGGGGCATGGTGCTGGCCGCTGTCGGGGGTCCC
CTGGTGGGGCTGGTGCTCCTCGTCATCCTGGTTACTGTCCTGCAGCGGCGCCGGCCGGCC
TGGCTGCCTGTCCGCCTGCGCTCCTGGGCCTGGCTCCCCGTCTGGCTCCATTCTCTGGAG
CCCTGGGACCGCCTGGTGACCCGCTGCTGCCCCTGCAACGTCTGCAGCCCCCCGAAGGCC
ACCACCAAAGAGGCCTACTGCTACGAGAACCCTGAGATCTTGGCCTCCCAGCAGTTGTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02690</identifier>
            <name>Na_Pi_cotrans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-dependent phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular phosphate ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>